On Tuesday, Shares of BlackBerry Limited (NASDAQ:BBRY), lost -1.82% to $7.56.
BlackBerry Limited unveiled the BlackBerry® Passport Silver Edition, a premium device built for business professionals who want a smartphone with the mobile tools they need to get things done - without sacrificing style or portability.
The BlackBerry Passport Silver Edition is in a class of its own, featuring a stunning silver finish with refined, curved corners, large square touch screen display and reinforced stainless steel frame for extra strength and durability. An essential business tool, the device delivers the same productivity enjoyed by other BlackBerry Passport products, in addition to an updated QWERTY touch-enabled keyboard, battery power that lasts more than a full day of mixed use, and BlackBerry® 10 OS 10.3.2.
BlackBerry Limited provides wireless communications solutions worldwide. The company offers BlackBerry wireless solutions, which comprise the sale of BlackBerry handheld devices; and the provision of data communication, and compression and security infrastructure services enabling BlackBerry handheld wireless devices to send and receive wireless messages and data.
Shares of Terex Corporation (NYSE:TEX), inclined 22.68% to $26.78, during its last trading session.
Terex Corporation and Konecranes jointly declared that their respective Boards of Directors have unanimously approved a definitive business combination agreement and the resulting all-stock merger of equals.
Konecranes and Terex will combine to create a single company with estimated pro forma 2014 revenues and EBITDA of $10.0 billion and $845 million, respectively. Upon completion of the transaction, Terex shareholders will own about 60% of the combined company and Konecranes shareholders will own about 40%. The new company will be named Konecranes Terex Plc and will be incorporated in Finland.
Terex Corporation operates as a lifting and material handling solutions company. Its Aerial Work Platforms segment designs, manufactures, services, and markets aerial work platform equipment, telehandlers, and light towers, in addition to related components and replacement parts under Terex and Genie names.
Finally, ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP), ended its last trade with -11.74% loss, and closed at $10.52.
ZIOPHARM Oncology declared financial results for the second quarter ended June 30, 2015, and offered an update on the company’s recent activities.
Recent Highlights
Ad-RTS-hIL-12
Ad-RTS-hIL-12 is a gene therapy candidate for the controlled expression of IL-12, a critical protein for stimulating an anti-cancer T cell immune response, using the RheoSwitch Therapeutic System(R) (RTS(R)) gene switch. In April 2015, ZIOPHARM declared the initiation of a Phase 1b/2 study of Ad-RTS-hIL-12 and veledimex following standard chemotherapy for the treatment of patients with locally advanced or metastatic breast cancer. In May 2015, the Company declared the initiation of a multi-center Phase 1 study of Ad-RTS-hIL-12 and veledimex in patients with recurrent or progressive glioblastoma multiforme, a form of brain cancer.
Both gene therapy trials, which are being conducted at leading centers across the U.S., are presently open and accruing patients. The Company anticipates that early results from each study will be presented at scientific meetings preceding to year end.
ZIOPHARM also declared in July that the U.S. Food and Drug Administration granted Orphan Drug Designation for Ad-RTS-hIL-12 and veledimex in the treatment of patients with malignant glioma. The FDA’s Office of Orphan Products grants orphan drug status to support development of medicines for underserved patient populations or rare disorders affecting fewer than 200,000 people in the U.S. Orphan Drug Designation provides eligibility for a seven-year period of market exclusivity in the United States after product approval, an accelerated review process, accelerated approval where appropriate, grant funding, tax benefits and an exemption from user fees.
ZIOPHARM Oncology, Inc., a biotechnology company, employs gene expression, control, and cell technologies to deliver cell-based therapies for the treatment of cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
